Vaccine aims to block return of aggressive breast cancer

NCT ID NCT03012100

Ongoing Disease control Sponsor: Academic and Community Cancer Research United Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a vaccine made from a protein found on many triple-negative breast cancer cells can help prevent the cancer from coming back. Participants receive the vaccine along with an immune booster and a low dose of chemotherapy. The study includes women with stage 1-3 triple-negative breast cancer who have already completed standard treatments like surgery and chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: multi-epitope folate receptor alpha peptide vaccine, sargramostim (GM-CSF), and cyclophosphamide
What this could lead to: If successful, this vaccine approach could help prevent triple-negative breast cancer from coming back after surgery and standard treatments.
What could go wrong: This is a phase 2 trial, so it is still early. The vaccine may not work for everyone, and side effects from the chemotherapy and vaccine are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILATERAL BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bilateral breast carcinoma breast cancer breast carcinoma breast neoplasm inflammatory breast carcinoma triple-negative breast carcinoma Unilateral Breast Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILATERAL BREAST CARCINOMA BREAST INFLAMMATORY CARCINOMA STAGE IB BREAST CANCER AJCC V7 STAGE II BREAST CANCER AJCC V6 AND V7 STAGE IIA BREAST CANCER AJCC V6 AND V7 STAGE IIB BREAST CANCER AJCC V6 AND V7 STAGE III BREAST CANCER AJCC V7 STAGE IIIA BREAST CANCER AJCC V7 STAGE IIIB BREAST CANCER AJCC V7 STAGE IIIC BREAST CANCER AJCC V7 TRIPLE-NEGATIVE BREAST CARCINOMA UNILATERAL BREAST CARCINOMA

Contacts and locations

Locations

Carle Cancer Center NCI Community Oncology Research Program

Urbana, Illinois, 61801, United States
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Inova Fairfax Hospital

Falls Church, Virginia, 22042, United States
Marshfield Medical Center-Marshfield

Marshfield, Wisconsin, 54449, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
Ochsner Medical Center Jefferson

New Orleans, Louisiana, 70121, United States
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.